Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. is engaged in research, development, manufacture, and marketing of proprietary respiratory support technology. The firm seeks to provide alternative to invasive mechanical ventilation. The company was founded by Dagi Ben Noon, Joe Hayon, and Dr. Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

RA'ANANA, Israel, Nov. 8, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the life support and respiratory treatment arena, is pleased to invite investors to a webinar on November 11, 2024, at 4:15 p.m.

Join Inspira™ Technologies' Live Investor Webinar and Q&A Session on November 11

The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the U.S. RA'ANANA, Israel , Oct. 24, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States.

Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100

RA'ANANA, Israel , Oct. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce the development of a new disposable kit for the perfusion market.

Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.

Inspira Stock to Gain From its Appearance at Annual ELSO Conference

RA'ANANA, Israel , Sept. 24, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.

Inspira™ Launches INSPIRA™ ART100 at the World's Largest Extracorporeal Life Support Conference

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

IINN Stock Gains on Second US Patent Approval for VORTX System

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry RA'ANANA, Israel , Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.

Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermittent actual blood samples, targets a potential $2.5 billion Point of Care testing and Arterial Blood Gas (ABG) analyzer market. RA'ANANA, Israel , Aug. 28, 2024  /PRNewswire/ -- Inspira Technologies OXY B.H.N.

Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

RA'ANANA, Israel , Aug. 22, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN)  (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, today announces the U.S. Food and Drug Administration ("FDA") listing of its medical cart (INSPIRA™ CART) which has been custom designed for use with the INSPIRA™ ART100 system.

Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product

RA'ANANA, Israel , Aug. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a trailblazer in life-support technology, today announced that it was approached by a leading medical technology company in the industry, to evaluate the operation of its proprietary key product in combination with the INSPIRA™ ART100 system.

Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow

Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hospitals, where the survival rate is less than 10%. The INSPIRA Cardi-ART provides the Company a new market opportunity to target the $39.8 billion global cardiac arrest market.

Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

Approval follows the FDA clearance announced on May 28, 2024  RA'ANANA, Israel , July 11, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is excited to announce the receipt of the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval for the INSPIRA™ ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system.

Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System

Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).

Inspira (IINN) Unveils Business Targets for 2024-25

Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel , June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr.

Inspira™ Announces Business Plan Targets

RA'ANANA, Israel , June 17, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce today that the Company will present at the annual iECOs Conference in Herzliya, Israel on June 18th, 2024.

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

First units expected to be shipped in Q4 2024. The Purchase Order follows the recent FDA Clearance of the INSPIRA™ ART100.

Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S.

The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel , June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024.

Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector

RA'ANANA, Israel , May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr.

Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments

Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.

Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant

RA'ANANA, Israel , May 28, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company", "Inspira", or "Inspira Technologies"), a breakthrough medical technology company, today announced that it has received notification of 510(k) class II clearance from the U.S. Food and Drug Administration (FDA) for its INSPIRA™ ART100, a Cardiopulmonary Bypass System.

INSPIRA™ ART100 Receives FDA 510(k) Clearance

RA'ANANA, Israel , May 2, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced the start of production of the INSPIRA ART100 medical device.

Inspira™ Announces Start of Production of the INSPIRA™ ART100

RA'ANANA, Israel , April 25, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device.

Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100

RA'ANANA, Israel , April 16, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is proud to announce the signing of a collaboration term sheet (the "Term Sheet") with the Beilinson Hospital in Israel for the evaluation of its proprietary INSPIRA ART100 device (the "Device") in organ transplant procedures.

News for Inspira Technologies Oxy BHN Ltd Stock (IINN)